Yuhuan Zheng1, Qiang Wang1, Tianshu Li1, Jianfei Qian1, Yong Lu1, Yi Li1, Enguang Bi1, Frederic Reu1, Yu Qin1, Judy Drazba1, Eric Hsi1, Jing Yang1, Zhen Cai1, Qing Yi1. 1. Affiliations of authors: Department of Hematology and State Key Laboratory of Biotherapy and Cancer Center, Sichuan University, West China Hospital, China (YZ); Department of Cancer Biology (YZ, QW, TL, JQ, YLu, YLi, EB, QY), Taussig Cancer Center (FR), Imaging Core Facility, Lerner Research Institute (JD), and Department of Pathology and Laboratory Medicine Institute (EH), Cleveland Clinic, Cleveland, OH; Department of Hematology, Zhejiang University, China (YLi, ZC); Department of Internal Medicine, Weiss Memory Hospital, Chicago, IL (YQ); Department of Lymphoma/Myeloma, MD Anderson Cancer Center, Houston, TX (JY).
Abstract
BACKGROUND: Multiple myeloma (MM) remains an incurable cancer characterized by accumulation of malignant plasma cells in the bone marrow (BM). The mechanism underlying MM homing to BM is poorly elucidated. METHODS: The clinical significance of migration inhibitory factor (MIF) expression was examined by analyzing six independent gene expression profile databases of primary MM cells using the Student's t test and Kaplan-Meier test. Enzyme-linked immunosorbent assay was used to examine MIF expression. In vivo bioluminescent imaging was used to determine MM cell localization and treatment efficacy in human MM xenograft mouse models, with three to four mice per group. MM cell attachment to BM stromal cells (BMSCs) was monitored by cell adhesion assay. MIF regulation of the expression of adhesion molecules was determined by chromatin immunoprecipitation (ChIP) assay. Statistical tests were two-sided. RESULTS: High levels of MIF were detected in MM BM (MIF level in BM plasma: healthy = 10.72 ± 5.788 ng/mL, n = 5; MM = 1811 ± 248.7 ng/mL, n = 10; P < .001) and associated with poor survival of patients (Kaplan-Meier test for MM OS: 87 MIF(high) patients, 86 MIF(low) patients, P = .02). Knocking down MIF impaired MM cell adhesion to BMSCs in vitro and led to formation of extramedullary tumors in SCID mice. MIF acted through surface receptor CXCR4 and adaptor COPS5 to regulate the expression of adhesion molecules ALCAM, ITGAV, and ITGB5 on MM cells. More importantly, MIF-deficient MM cells were sensitive to chemotherapy in vitro when cocultured with BMSCs and in vivo. MIF inhibitor 4-IPP sensitized MM cells to chemotherapy. CONCLUSIONS: MIF is an important player and a novel therapeutic target in MM. Inhibiting MIF activity will sensitize MM cells to chemotherapy.
BACKGROUND:Multiple myeloma (MM) remains an incurable cancer characterized by accumulation of malignant plasma cells in the bone marrow (BM). The mechanism underlying MM homing to BM is poorly elucidated. METHODS: The clinical significance of migration inhibitory factor (MIF) expression was examined by analyzing six independent gene expression profile databases of primary MM cells using the Student's t test and Kaplan-Meier test. Enzyme-linked immunosorbent assay was used to examine MIF expression. In vivo bioluminescent imaging was used to determine MM cell localization and treatment efficacy in human MM xenograft mouse models, with three to four mice per group. MM cell attachment to BM stromal cells (BMSCs) was monitored by cell adhesion assay. MIF regulation of the expression of adhesion molecules was determined by chromatin immunoprecipitation (ChIP) assay. Statistical tests were two-sided. RESULTS: High levels of MIF were detected in MM BM (MIF level in BM plasma: healthy = 10.72 ± 5.788 ng/mL, n = 5; MM = 1811 ± 248.7 ng/mL, n = 10; P < .001) and associated with poor survival of patients (Kaplan-Meier test for MM OS: 87 MIF(high) patients, 86 MIF(low) patients, P = .02). Knocking down MIF impaired MM cell adhesion to BMSCs in vitro and led to formation of extramedullary tumors in SCIDmice. MIF acted through surface receptor CXCR4 and adaptor COPS5 to regulate the expression of adhesion molecules ALCAM, ITGAV, and ITGB5 on MM cells. More importantly, MIF-deficient MM cells were sensitive to chemotherapy in vitro when cocultured with BMSCs and in vivo. MIF inhibitor 4-IPP sensitized MM cells to chemotherapy. CONCLUSIONS:MIF is an important player and a novel therapeutic target in MM. Inhibiting MIF activity will sensitize MM cells to chemotherapy.
Authors: Fenghuang Zhan; Johanna Hardin; Bob Kordsmeier; Klaus Bumm; Mingzhong Zheng; Erming Tian; Ralph Sanderson; Yang Yang; Carla Wilson; Maurizio Zangari; Elias Anaissie; Christopher Morris; Firas Muwalla; Frits van Rhee; Athanasios Fassas; John Crowley; Guido Tricot; Bart Barlogie; John Shaughnessy Journal: Blood Date: 2002-03-01 Impact factor: 22.113
Authors: George Mulligan; Constantine Mitsiades; Barb Bryant; Fenghuang Zhan; Wee J Chng; Steven Roels; Erik Koenig; Andrew Fergus; Yongsheng Huang; Paul Richardson; William L Trepicchio; Annemiek Broyl; Pieter Sonneveld; John D Shaughnessy; P Leif Bergsagel; David Schenkein; Dixie-Lee Esseltine; Anthony Boral; Kenneth C Anderson Journal: Blood Date: 2006-12-21 Impact factor: 22.113
Authors: Abdel Kareem Azab; Phong Quang; Feda Azab; Costas Pitsillides; Brian Thompson; Triona Chonghaile; John T Patton; Patricia Maiso; Val Monrose; Antonio Sacco; Hai T Ngo; Ludmila M Flores; Charles P Lin; John L Magnani; Andrew L Kung; Anthony Letai; Ruben Carrasco; Aldo M Roccaro; Irene M Ghobrial Journal: Blood Date: 2011-11-16 Impact factor: 22.113
Authors: Lukas Orel; Hannah Neumeier; Karin Hochrainer; Bernd R Binder; Johannes A Schmid Journal: J Cell Mol Med Date: 2009-07-28 Impact factor: 5.310
Authors: Rachel E Piddock; Christopher R Marlein; Amina Abdul-Aziz; Manar S Shafat; Martin J Auger; Kristian M Bowles; Stuart A Rushworth Journal: J Hematol Oncol Date: 2018-05-16 Impact factor: 17.388